Quarterly report pursuant to Section 13 or 15(d)

EQUITY (Details Narrative)

v3.10.0.1
EQUITY (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 08, 2018
Mar. 03, 2017
May 31, 2018
Mar. 27, 2018
Jun. 30, 2017
Apr. 19, 2017
Mar. 31, 2017
Sep. 30, 2018
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Preferred stock, authorised               10,000,000 10,000,000   10,000,000
Preferred stock, par value (in dollars per share)               $ 0.0001 $ 0.0001   $ 0.0001
Common stock, authorised               490,000,000 490,000,000   490,000,000
Common stock, par value (in dollars per share)               $ 0.0001 $ 0.0001   $ 0.0001
Preferred stock, issued               0 0   0
Preferred stock, outstanding               0 0   0
Common stock, issued               73,560,751 73,560,751   70,278,622
Common stock, outstanding               73,040,751 73,040,751   70,278,622
Stock warrants issued                 578,891    
Warrants exercise price               $ 1.28 $ 1.28  
Common shares issued for services                 $ 634,950    
Stock-based compensation expense                 2,224,969 $ 602,224  
Term           1 year          
Aggregate intrinsic value of the warrants outstanding               $ 879,784 879,784    
Aggregate intrinsic value of the warrants exercisable               879,784 879,784    
Employee Stock Option [Member]                      
Aggregate fair value of options granted                 446,911    
Compensation and related benefits               147,715 299,195    
Aggregate value of nonvested options               1,293,818 $ 1,293,818    
Amortization of stock-based compensation expense                 1 year 3 months 29 days    
Intrinsic value of stock options outstanding               4,824,600 $ 4,824,600    
Intrinsic value of stock options exercisable               2,743,155 2,743,155    
Non Employee Stock Option [Member]                      
Compensation and related benefits               221,040 604,082    
Aggregate value of nonvested options               120,225 $ 120,225    
Amortization of stock-based compensation expense                 10 months 17 days    
Intrinsic value of stock options outstanding               648,000 $ 648,000    
Intrinsic value of stock options exercisable               $ 486,000 $ 486,000    
DOING Biomedical Technology Co., Ltd                      
Related party repayment obligation     $ 1,000,000                
Third party                      
Common stock repurchased, Shares       520,000              
Common stock repurchased, Value       $ 522,500              
Escrow agent                      
Share repurchase cost       $ 2,500              
Accredited investor                      
Common stock issued, Shares 2,000,000                    
Common stock issued, Value $ 2,000,000                    
Subscription Agreement | Private Placement [Member]                      
Stock warrants issued               218,391      
Subscription Agreement | Private Placement One [Member]                      
Stock warrants issued               151,235      
Warrants exercise price               $ 1.62 $ 1.62    
Subscription Agreement | Private Placement Two [Member]                      
Stock warrants issued               5,960      
Warrants exercise price               $ 1.85 1.85    
Subscription Agreement | Private Placement Three [Member]                      
Stock warrants issued               36,750      
Warrants exercise price               $ 1.90 1.90    
Subscription Agreement | Private Placement Four [Member]                      
Stock warrants issued               24,446      
Warrants exercise price               $ 2.24 $ 2.24    
Subscription Agreement | Investor                      
Common shares sold for cash                 $ 7,064,717    
Common shares sold for cash (in shares)                 3,107,000    
Warrants term               5 years 5 years    
Share price               $ 1.75 $ 1.75    
Subscription Agreement | Accredited investor                      
Common stock issued, Shares   3,000,000         2,000,000        
Common stock issued, Value   $ 3,000,000                  
Subscription Agreement | Accredited investor | Avalon (Shanghai) Healthcare Technology Co., Ltd.                      
Annual interest         20.00%            
Share price                   $ 1.20  
Term         3 years            
Consulting agreements | Consulting companies [Member]                      
Common shares issued for services                 $ 634,950    
Common shares issued for services (in shares)                 235,679    
Stock-based compensation expense               $ 529,965 $ 591,715    
Decrease in accrued liabilities               10,000      
Prepaid expense               $ 33,235 $ 33,235